No Data
China Resources Medical Holdings Insider Lowered Holding By 100% During Last Year
cr medical (01515.HK): Income has slightly fluctuated in the short term, and it is worth looking forward to profit optimization.
Event: Overall performance meets expectations, profit level improves. The company released the 2024 interim report, achieving revenue of 4.976 billion yuan in 2024H1, a decrease of 2.7% year-on-year, net income of 0.434 billion yuan, an increase of 9.0% year-on-year.
cr medical (01515.HK) received shareholding of 0.849 million shares of common stock from Fidelity International and its affiliates, worth approximately 3.5041 million Hong Kong dollars.
Reported on October 21st, according to the documents disclosed by the Hong Kong Stock Exchange on October 21st, FIL Limited increased its shareholding in cr medical (01515.HK) by an average price of HK$4.1273 per share on October 15, acquiring 0.849 million ordinary shares, worth approximately HK$3.5041 million. After the increase, FIL Limited's latest number of shares held is 78.5035 million shares, and the holding proportion has risen from 5.99% to 6.05%. This trade involves other related parties: Pandanus Associates Inc. and Pandanus.
CR Medical (01515.HK) received an increase in shareholding of 5.67 million ordinary shares by Fidelity International and related parties, worth approximately 26.226 million Hong Kong dollars.
On October 8th, according to the documents disclosed by the Hong Kong Stock Exchange on October 8th, FIL Limited increased its shareholding in cr medical (01515.HK) by an average price of HK$4.6254 per share on October 2, with a total of 5.67 million shares of common stock, worth approximately HK$26.226 million. After the increase, FIL International's latest number of shares held is 70.434 million shares, and the beneficial ownership ratio has increased from 4.99% to 5.43%. This trade involves other related parties: Pandanus Partners L.P. and Pandanus.
GF Securities: Maintains a "buy" rating for CR Medical (01515) with a fair value of 5.98 Hong Kong dollars.
gf sec expects cr medical's 24-year net income attributable to mother to increase by 8.6% compared to 23-year, excluding the devaluation of Huaiyin of 0.644 billion.
CR MEDICAL: Interim Report 2024
No Data
No Data